Target Price | $7.60 |
Price | $3.99 |
Potential |
90.48%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Aclaris Therapeutics, Inc. 2025 .
The average Aclaris Therapeutics, Inc. target price is $7.60.
This is
90.48%
register free of charge
$13.00
225.81%
register free of charge
$3.00
24.81%
register free of charge
|
|
A rating was issued by 7 analysts: 5 Analysts recommend Aclaris Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Aclaris Therapeutics, Inc. stock has an average upside potential 2025 of
90.48%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 31.25 | 11.44 |
5.04% | 63.39% | |
EBITDA Margin | -363.74% | -798.97% |
28.28% | 119.65% | |
Net Margin | -290.25% | -461.98% |
9.09% | 59.17% |
7 Analysts have issued a sales forecast Aclaris Therapeutics, Inc. 2024 . The average Aclaris Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Aclaris Therapeutics, Inc. 2024 . The average Aclaris Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Aclaris Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Aclaris Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.27 | -0.74 |
4.51% | 41.73% | |
P/E | negative | |
EV/Sales | 13.99 |
7 Analysts have issued a Aclaris Therapeutics, Inc. forecast for earnings per share. The average Aclaris Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Aclaris Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Aclaris Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.